<?xml version="1.0" encoding="UTF-8"?>
<ref id="hep41480-bib-0072">
 <label>72</label>
 <mixed-citation publication-type="journal" id="hep41480-cit-0072">
  <string-name>
   <surname>Koh</surname>
   <given-names>C</given-names>
  </string-name>, 
  <string-name>
   <surname>Canini</surname>
   <given-names>L</given-names>
  </string-name>, 
  <string-name>
   <surname>Dahari</surname>
   <given-names>H</given-names>
  </string-name>, 
  <string-name>
   <surname>Zhao</surname>
   <given-names>X</given-names>
  </string-name>, 
  <string-name>
   <surname>Uprichard</surname>
   <given-names>SL</given-names>
  </string-name>, 
  <string-name>
   <surname>Haynes‐Williams</surname>
   <given-names>V</given-names>
  </string-name>, et al. 
  <article-title>Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof‐of‐concept randomised, double‐blind, placebo‐controlled phase 2A trial</article-title>. 
  <source xml:lang="en">Lancet Infect Dis</source>
  <year>2015</year>;
  <volume>15</volume>:
  <fpage>1167</fpage>‐
  <lpage>1174</lpage>.
  <pub-id pub-id-type="pmid">26189433</pub-id>
 </mixed-citation>
</ref>
